España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
INmune Bio
INMB
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$7.67
1.14
17.55%
At close: -
$7.80
0.13
1.69%
After Hours: 4:25 PM EDT
Get Report
Comment
INmune Bio (INMB) Forecast
News
Earnings
INmune Bio (INMB) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for INmune Bio (NASDAQ:INMB) Stock
INmune Bio Stock (NASDAQ: INMB)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, December 04, 2024
OmniScience And INmune Bio Partner To Acceler...
Benzinga Newsdesk
Wednesday, November 13, 2024
INmune Bio Completed Randomization Of Patient...
Benzinga Newsdesk
Thursday, October 31, 2024
INmune Bio Q3 EPS $(0.60) Misses $(0.50) Esti...
Benzinga Newsdesk
Monday, October 28, 2024
INmune Bio shares are trading higher after th...
Benzinga Newsdesk
INmune Bio Inc. To Host Webinar On Cognitive ...
Benzinga Newsdesk
Thursday, October 24, 2024
INmune Bio Announces Publication In Cell Repo...
Benzinga Newsdesk
Monday, October 21, 2024
Alliance Global Partners Initiates Coverage O...
Benzinga Newsdesk
Monday, September 30, 2024
INmune Bio Inc. Completes Enrollment For Phas...
Benzinga Newsdesk
Friday, September 27, 2024
Raymond James Initiates Coverage On INmune Bi...
Benzinga Newsdesk
Thursday, September 26, 2024
INmune Bio shares are trading higher after th...
Benzinga Newsdesk
INmune Bio's INKmune Demonstrates Excellent S...
Benzinga Newsdesk
Tuesday, September 17, 2024
INmune Bio Announces Results Of Additional Bl...
Benzinga Newsdesk
Friday, September 13, 2024
Inmune Bio shares are trading lower after the...
Benzinga Newsdesk
INmune Bio Announces $13M Registered Direct O...
Benzinga Newsdesk
Thursday, August 22, 2024
Scotiabank Initiates Coverage On INmune Bio w...
Benzinga Newsdesk
Thursday, August 01, 2024
INmune Bio Q2 2024 GAAP EPS $(0.50) Beats $(0...
Benzinga Newsdesk
Monday, July 29, 2024
INmune Bio Presents New Phase 1 Study Data De...
Benzinga Newsdesk
Tuesday, July 23, 2024
INmune Highlights Publication Titled 'Proteom...
Benzinga Newsdesk
Thursday, June 27, 2024
INmune Bio Completes Blinded Interim Analysis...
Benzinga Newsdesk
Thursday, June 20, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
Thursday, May 30, 2024
INmune Bio To Join Russell 3000 Index, Effect...
Benzinga Newsdesk
Thursday, May 09, 2024
INmune Bio Q1 2024 GAAP EPS $(0.61) Misses $(...
Benzinga Newsdesk
Tuesday, April 30, 2024
INmune Bio Provides Update On Two Patients Fr...
Benzinga Newsdesk
Monday, April 29, 2024
INmune Bio Completes First Cohort And Initiat...
Benzinga Newsdesk
Thursday, April 25, 2024
INmune Bio Says Remains On Track In Line With...
Benzinga Newsdesk
INmune Bio Announces $9.7M Registered Direct ...
Benzinga Newsdesk
Tuesday, April 23, 2024
INmune Bio Announces 24-Month Stability Valid...
Benzinga Newsdesk
Monday, April 22, 2024
INmune Bio Inc. Raises ~$4.8M In Gross Procee...
Benzinga Newsdesk
Monday, April 08, 2024
INmune Bio Inc. Presents Data On INB03's Role...
Benzinga Newsdesk
Thursday, March 28, 2024
INmune Bio: Q4 Earnings Insights
Benzinga Insights
INmune Bio Q4 EPS $(0.47) Misses $(0.44) Esti...
Benzinga Newsdesk
Earnings Scheduled For March 28, 2024
Benzinga Insights
Wednesday, March 27, 2024
A Preview Of INmune Bio's Earnings
Benzinga Insights
Tuesday, March 05, 2024
INmune Bio Reports Significant EEG Improvemen...
Benzinga Newsdesk
Tuesday, January 30, 2024
INmune Bio Announces FDA Removal Of Clinical ...
Benzinga Newsdesk
Monday, January 22, 2024
On Jan 16, Elevai Labs Inc Entered Into A Lic...
Benzinga Newsdesk
Tuesday, January 16, 2024
Why Elevai Labs Stock Is Trading Higher
Erica Kollmann
ELEVAI Labs Signs Exclusive Worldwide Manufac...
Benzinga Newsdesk
Tuesday, January 02, 2024
INmune Bio Dosed The First Patient In The Pha...
Benzinga Newsdesk
Monday, December 18, 2023
INmune Bio On Track To Complete Enrollment Of...
Benzinga Newsdesk
Wednesday, November 29, 2023
INmune Bio Inc. Demonstrates that INB03 Enhan...
Benzinga Newsdesk
Monday, November 27, 2023
INmune Bio Has Received European Medicines Ag...
Benzinga Newsdesk
Wednesday, November 15, 2023
INmune Bio Inc. Announces Expansion Of Phase ...
Benzinga Newsdesk
Wednesday, November 01, 2023
INmune Bio Q3 2023 Gaap EPS $(0.48) Misses $...
Benzinga Newsdesk
Earnings Scheduled For November 1, 2023
Benzinga Insights
Tuesday, October 31, 2023
INmune Bio Inc. Patent Claims Covering INB16 ...
Benzinga Newsdesk
Monday, October 30, 2023
INmune Bio Inc. Presents Preclinical Data At ...
Benzinga Newsdesk
Tuesday, October 17, 2023
INmune Bio Inc. To Present New Biomarker And ...
Benzinga Newsdesk
Tuesday, September 05, 2023
INmune Bio Inc. Announces Approval Of Clinical Trial Application By The U.K. Medicines And Healthcare Products Regulatory Agency For Phase 2 Clinical Trial In Alzheimer's Disease
Happy Mohamed
Monday, August 07, 2023
INmune Bio Q2 EPS $(0.36) Beats $(0.40) Estim...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
